A promising approach using implantable microdevices allows real-time evaluation of chemotherapy responses in pancreatic ductal adenocarcinoma (PDAC).
- In a study with mouse models, the device enabled localized delivery of chemotherapy agents and real-time monitoring of tumor response.
- Significant reductions in tumor cell proliferation were observed after treatment, indicating drug-specific effects.
This method could advance precision medicine by guiding intra-operative decisions based on individual tumor responses.
- The strongest markers of treatment effect were seen 24 hours post-implantation, emphasizing the importance of timing in therapeutic assessment.
Journal Article by Standring OJ, Hohenleitner JT (…) Weiss MJ et 14 al. in Ann Surg
Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc.
